Alkermes Inc. plc
ALKS Real Time Price USDRecent trades of ALKS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ALKS holdings by institutional investors
Quarterly net insider trading by ALKS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
ALKS Estimated quarterly lobbying spending
ALKS Revenue by Segment or Geography
New ALKS patent grants
-
Patent Title: Substituted piperidino compounds and related methods of treatment Oct. 14, 2025
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Aug. 06, 2024
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Jun. 11, 2024
-
Patent Title: Bicyclic inhibitors of histone deacetylase May. 21, 2024
-
Patent Title: Substituted pyridines as inhibitors of histone deacetylase Feb. 27, 2024
-
Patent Title: Hetero-halo inhibitors of histone deacetylase Jan. 02, 2024
-
Patent Title: Substituted piperidino compounds and related methods of treatment Sep. 19, 2023
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Jan. 03, 2023
-
Patent Title: Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties Dec. 27, 2022
-
Patent Title: Bicyclic inhibitors of histone deacetylase Mar. 29, 2022
-
Patent Title: Bicyclic inhibitors of histone deacetylase Jan. 18, 2022
-
Patent Title: Substituted pyridines as inhibitors of histone deacetylase Jan. 18, 2022
-
Patent Title: Hetero-halo inhibitors of histone deacetylase Feb. 16, 2021
-
Patent Title: Single chain fc fusion proteins Jan. 05, 2021
-
Patent Title: Compositions for modulating il-10 immunostimulatory and anti-inflammatory properties Jul. 02, 2019
-
Patent Title: Fusion polypeptides comprising mucin-domain polypeptide linkers Jan. 22, 2019
-
Patent Title: Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide Jul. 17, 2018
-
Patent Title: Peripherally acting opioid compounds Oct. 03, 2017
-
Patent Title: Ligands modified by circular permutation as agonists and antagonists Aug. 30, 2016
-
Patent Title: Peripherally acting opioid compounds Aug. 16, 2016
-
Patent Title: Ligands modified by circular permutation as agonists and antagonists Jun. 07, 2016
-
Patent Title: Fusion polypeptides comprising mucin-domain polypeptide linkers Mar. 29, 2016
-
Patent Title: Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide Oct. 13, 2015
-
Patent Title: Selective opioid compounds May. 26, 2015
-
Patent Title: Process for the synthesis of quaternary amine compounds May. 12, 2015
-
Patent Title: Polymorphic forms of naltrexone Mar. 10, 2015
-
Patent Title: Peripherally acting opioid compounds Feb. 24, 2015
-
Patent Title: Polymorphic forms of naltrexone May. 27, 2014
-
Patent Title: Polymorphic forms of naltrexone Mar. 05, 2013
-
Patent Title: Selective opioid compounds Jan. 15, 2013
-
Patent Title: Methods for administering aripiprazole Dec. 25, 2012
-
Patent Title: Methods for administering aripiprazole Dec. 25, 2012
-
Patent Title: Naltrexone long acting formulations and methods of use Apr. 05, 2011
-
Patent Title: Pulmonary delivery for levodopa Feb. 01, 2011
-
Patent Title: Residual solvent extraction method and microparticles produced thereby Jan. 25, 2011
-
Patent Title: Formulations for spray-drying large porous particles Oct. 05, 2010
-
Patent Title: Inhalable sustained therapeutic formulations Jul. 13, 2010
-
Patent Title: Particles for inhalation having sustained release properties Mar. 16, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ALKS from public contracts
Recent insights relating to ALKS
Recent picks made for ALKS stock on CNBC
ETFs with the largest estimated holdings in ALKS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ALKS stock a Buy, Sell, or Hold?
- What is the price target for $ALKS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ALKS stock?
- Who owns the most shares of $ALKS stock?
- What funds own $ALKS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALKS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Address Dublin 4, L2
- Market Cap 4.7 billion
- Employees 1,800
- Industrial Classification Pharmaceutical Preparations